Margarett24 / Shutterstock.com
13 October 2022Big PharmaMuireann Bolger
Pharma company raises pressure with hypotension drug lawsuit
Nexus raises second complaint against same parties in a month | Ready-to-use drug that can raise the blood pressure of hypotension patients at issue.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Americas
19 August 2021 Nexus Pharmaceuticals and rival Nevakar have gone to court to determine which company has the right to sell a new hypotension drug, which can be administered to patients under anesthesia during surgery.
Americas
29 July 2021 The US Food and Drug Administration has approved the first-ever interchangeable biosimilar product, an insulin treatment for Types 1 and 2 diabetes.
Editor's picks
Editor's picks
Americas
19 August 2021 Nexus Pharmaceuticals and rival Nevakar have gone to court to determine which company has the right to sell a new hypotension drug, which can be administered to patients under anesthesia during surgery.
Americas
29 July 2021 The US Food and Drug Administration has approved the first-ever interchangeable biosimilar product, an insulin treatment for Types 1 and 2 diabetes.
Americas
19 August 2021 Nexus Pharmaceuticals and rival Nevakar have gone to court to determine which company has the right to sell a new hypotension drug, which can be administered to patients under anesthesia during surgery.
Americas
29 July 2021 The US Food and Drug Administration has approved the first-ever interchangeable biosimilar product, an insulin treatment for Types 1 and 2 diabetes.